China
Africa
Explore chapters and articles related to this topic
Marine Chondroitin Sulfate and Its Potential Applications
Published in Se-Kwon Kim, Marine Biochemistry, 2023
There were no histopathological alterations in intestinal tissue in rabbit tests, indicating that the liposomal formulation employed was safe. As a result, liposomes can be regarded as a viable oral permeation enhancer system for glucosamine sulfate and chondroitin sulfate, even though bioavailability studies are still warranted (Agiba et al., 2018). In comparison to placebo, glucosamine and chondroitin sulfate offered statistically significant pain alleviation (Barrow, 2010). A study revealed that a single dosage of up to four capsules containing 500 mg chondroitin sulfate and 400 mg glucosamine sulfate was well tolerated, with a profile that was consistent with 12-hour treatment (Toffoletto et al., 2005). Preventive therapy, larger dosages and multimodality methods with certain combination treatments were all linked to beneficial effects of glucosamine and chondroitin sulfate treatments (Fernández-Martín et al., 2021). In long-term usage, a combination of oral chondroprotective glucosamine and chondroitin sulfate has shown efficacy in modifying osteoarthritis while also having a favorable safety profile (Agiba, 2017).
Biophysical Stimulation of Articular Cartilage for Chondroprotection and Chondroregeneration
Published in Marko S. Markov, James T. Ryaby, Erik I. Waldorff, Pulsed Electromagnetic Fields for Clinical Applications, 2020
Simona Salati, Stefania Setti, Ruggero Cadossi
During inflammation, the physiological maintenance of the cartilage, which is guaranteed by the balance between anabolic and catabolic activity, is lost. Once cartilage loss has begun, it progresses through a mixture of mechanical and biological events. Owing to the low reparative capacity of the cartilage, it is of utmost importance to develop chondroprotective treatments aimed at limiting the damage of cartilage following injury, increasing the reparative response and finally preventing degeneration.
Development of solid lipid nanoparticles of diacerein in a stable oral liquid dosage form using a central composite design
Published in Journal of Dispersion Science and Technology, 2023
Mayyas Al-Remawi, Amani Elsayed, Ala’a Saleem, Mohammad Saleem
Diacerein (DCN) is an anthraquinone medication that works slowly and is used to treat joint conditions, such as osteoarthritis. It has anti-inflammatory, analgesic, antioxidant and anti-apoptosis effects.[1] Its action is exerted by inhibiting the interleukin-1 β system and its related downstream signaling. The European Medicines Agency (EMA)’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the suspension of DCN-containing medicines across the EU due to the risk of severe diarrhea and potentially harmful effects on the liver. However, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) concluded that the benefit-to-risk balance of DCN remains positive in the symptomatic treatment of hip and knee osteoarthritis.[2] Thus, it is mainly used as a chondroprotective agent, i.e., it protects and prevents loss of articular cartilage; thus, it does more than just relieve the sensation of pain. Recently, it was investigated for the treatment of different ailments, such as diabetes mellitus, cancer, kidney injury, ulcerative colitis, testicular toxicity and pain.[3–5]